APA (7th ed.) Citation

OM, F., A, G., NU, L., M, F., S, C., T, O., . . . EL, M. (2021). A dynamic portrait of adverse events for breast cancer patients: Results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast cancer research and treatment, 185(1), 135. https://doi.org/10.1007/s10549-020-05928-4

Chicago Style (17th ed.) Citation

OM, Filho, et al. "A Dynamic Portrait of Adverse Events for Breast Cancer Patients: Results from a Phase II Clinical Trial of Eribulin in Advanced HER2-negative Breast Cancer." Breast Cancer Research and Treatment 185, no. 1 (2021): 135. https://doi.org/10.1007/s10549-020-05928-4.

MLA (9th ed.) Citation

OM, Filho, et al. "A Dynamic Portrait of Adverse Events for Breast Cancer Patients: Results from a Phase II Clinical Trial of Eribulin in Advanced HER2-negative Breast Cancer." Breast Cancer Research and Treatment, vol. 185, no. 1, 2021, p. 135, https://doi.org/10.1007/s10549-020-05928-4.